The Estrogen Receptor (ER), Progesterone Receptor (PR), Human Epidermal Growth Factor Receptor 2 (HER2), and Ki67 antigen are the four biomarkers routinely examined in BC biopsies and excision specimens due to their potential impact on heterogeneity prognosis and clinical therapy. Here, ESR1 is linked to breast cancer.